Minireview: New molecular mediators of glucocorticoid receptor activity in metabolic tissues

Molecular Endocrinology

Volumn 28, Issue 7, 2014, Pages 999-1011

  Patel, Rucha ^a   Williams Dautovich, Jasmine ^a   Cummins, Carolyn L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Banting and Best Diabetes Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; FARNESOID X RECEPTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOSE 6 PHOSPHATASE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEPATOCYTE NUCLEAR FACTOR 3; HEPATOCYTE NUCLEAR FACTOR 4; HISTONE DEACETYLASE 3; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN RECEPTOR SUBSTRATE 1; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TRANSCRIPTION FACTOR FKHRL1; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL OBESITY; ADIPOGENESIS; ADIPOSE TISSUE; BINDING SITE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CUSHING SYNDROME; ENZYME PHOSPHORYLATION; FATTY LIVER; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; METABOLIC DISORDER; MUSCLE ATROPHY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; HUMAN; INFLAMMATION; LIVER; METABOLISM; MOUSE; MUSCLE; PANCREAS; PHYSIOLOGY;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMALS; GLUCOCORTICOIDS; GLUCONEOGENESIS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INFLAMMATION; LIPOGENESIS; LIPOLYSIS; LIVER; MICE; MUSCLES; PANCREAS; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84903575036     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1062     Document Type: Review

References (145)

1. Oakley RH, Cidlowski JA. Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J Biol Chem. 2011; 286(5):3177-3184.
2. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol. 2007;275(1-2):43-61.
3. Lewis RL, Roger A. The effect of the adrenal cortex on carbohydrate metabolism. Endocrinology. 1940(27):971.
4. Sakoda H, Ogihara T, Anai M, et al. Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes. 2000;49(10):1700-1708.
5. Weinstein SP, Wilson CM, Pritsker A, Cushman SW. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism. 1998;47(1):3-6.
6. Hasselgren PO. Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care. 1999;2(3):201-205.
7. Divertie GD, Jensen MD, Miles JM. Stimulation of lipolysis in humans by physiological hypercortisolemia. Diabetes. 1991; 40(10):1228-1232.
8. Guillaume-Gentil C, Assimacopoulos-Jeannet F, Jeanrenaud B. Involvement of non-esterified fatty acid oxidation in glucocorticoidinduced peripheral insulin resistance in vivo in rats. Diabetologia. 1993;36(10):899-906.
9. Odedra BR, Bates PC, Millward DJ. Time course of the effect of catabolic doses of corticosterone on protein turnover in rat skeletal muscle and liver. Biochem J. 1983;214(2):617-627.
10. Munck A. Glucocorticoid inhibition of glucose uptake by peripheral tissues: old and new evidence, molecular mechanisms, and physiological significance. Perspect Biol Med. 1971;14(2):265-269.
11. Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest. 1997;99(3):414-423.
12. Rose AJ, Herzig S. Metabolic control through glucocorticoid hormones: an update. Mol Cell Endocrinol. 2013;380(1-2):65-78.
13. Reynolds RM, Walker BR, Syddall HE, Whorwood CB, Wood PJ, Phillips DI. Elevated plasma cortisol in glucose-intolerant men: differences in responses to glucose and habituation to venepuncture. J Clin Endocrinol Metab. 2001;86(3):1149-1153.
14. Ohshima K, Shargill NS, Chan TM, Bray GA. Adrenalectomy reverses insulin resistance in muscle from obese (ob/ob) mice. AmJ Physiol. 1984;246(2 Pt 1):E193-E197.
15. Livingstone DE, Grassick SL, Currie GL, Walker BR, Andrew R. Dysregulation of glucocorticoid metabolism in murine obesity: comparable effects of leptin resistance and deficiency. J Endocrinol. 2009;201(2):211-8.
16. Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing's syndrome. Am J Med. 1952;13(5):597-614.
17. Rockall AG, Sohaib SA, Evans D, et al. Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol. 2003;149(6):543-548.
18. Shimomura Y, Bray GA, Lee M. Adrenalectomy and steroid treatment in obese (ob/ob) and diabetic (db/db) mice. Horm Metab Res. 1987;19(7):295-299.
19. Liu Y, Nakagawa Y, Wang Y, et al. Increased glucocorticoid receptor and 11β-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice. Diabetes. 2005;54(1):32-40.
20. Friedman JE, Sun Y, Ishizuka T, et al. Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice. J Biol Chem. 1997;272(50):31475-31481.
21. Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2013;65(2):294-298.
22. Scerif M, Fuzesi T, Thomas JD, et al. CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus. J Endocrinol. 2013;219(1):79-88.
23. Wise JK, Hendler R, Felig P. Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. J Clin Invest. 1973;52(11):2774-2782.
24. Brennan-Speranza TC, Henneicke H, Gasparini SJ, et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Invest. 2012;122(11):4172-4189.
25. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab. 1982;54(1):131-138.
26. Patel R, Patel M, Tsai R, et al. LXRβ is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J Clin Invest. 2011;121(1):431-441.
27. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23-43.
28. Vandevyver S, Dejager L, Tuckermann J, Libert C. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology. 2013;154(3):993-1007.
29. Nixon M, Andrew R, Chapman KE. It takes two to tango: dimerisation of glucocorticoid receptor and its anti-inflammatory functions. Steroids. 2013;78(1):59-68.
30. Uhlenhaut NH, Barish GD, Yu RT, et al. Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol Cell. 2013;49(1):158-171.
31. Shipp LE, Lee JV, Yu CY, et al. Transcriptional regulation of human dual specificity protein phosphatase 1 (DUSP1) gene by glucocorticoids. PLoS One. 2010;5(10): e13754.
32. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science. 2009;324(5925):407-410.
33. So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR. Determinants of cell-and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet. 2007;3(6):e94.
34. John S, Sabo PJ, Thurman RE, et al. Chromatin accessibility predetermines glucocorticoid receptor binding patterns. Nat Genet. 2011;43(3):264-268.
35. Biddie SC, John S, Sabo PJ, et al. Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding. Mol Cell. 2011;43(1):145-155.
36. Kassel O, Herrlich P. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol Cell Endocrinol. 2007;275(1-2):13-29.
37. Phuc Le P, Friedman JR, Schug J, et al. Glucocorticoid receptordependent gene regulatory networks. PLoS Genet. 2005;1(2):e16.
38. Stahn C, Lowenberg M, Hommes DW, et al. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol. 2007;275(1-2):71-78.
39. Lowenberg M, Tuynman J, Scheffer M, et al. Kinome analysis reveals nongenomic glucocorticoid receptor-dependent inhibition of insulin signaling. Endocrinology. 2006;147(7):3555-3562.
40. Kuo T, Lew MJ, Mayba O, Harris CA, Speed TP, Wang JC. Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling. Proc Natl Acad Sci USA. 2012;109(28):11160-11165.
41. Reddy TE, Pauli F, Sprouse RO, et al. Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. Genome Res. 2009;19(12):2163-2171.
42. Reddy TE, Gertz J, Crawford GE, Garabedian MJ, Myers RM. The hypersensitive glucocorticoid response specifically regulates period 1 and expression of circadian genes. Mol Cell Biol. 2012; 32(18):3756-3767.
43. Grøntved L, John S, Baek S, et al. C/EBP maintains chromatin accessibility in liver and facilitates glucocorticoid receptor recruitment to steroid response elements. EMBO J. 2013;32(11):1568-1583.
44. Chakravarty K, Cassuto H, Reshef L, Hanson RW. Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C. Crit Rev Biochem Mol Biol. 2005; 40(3):129-154.
45. Steger DJ, Grant GR, Schupp M, et al. Propagation of adipogenic signals through an epigenomic transition state. Genes Dev. 2010; 24(10):1035-1044.
46. Gathercole LL, Lavery GG, Morgan SA, et al. 11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocr Rev. 2013;34(4):525-555.
47. Hers HG, Hue L. Gluconeogenesis and related aspects of glycolysis. Annu Rev Biochem. 1983;52:617-653.
48. Vander Kooi BT, Onuma H, Oeser JK, et al. The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative glucocorticoid response elements. Mol Endocrinol. 2005;19(12):3001-3022.
49. Imai E, Miner JN, Mitchell JA, Yamamoto KR, Granner DK, et al. Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids. J Biol Chem. 1993;268(8):5353-5356.
50. Hall RK, Sladek FM, Granner DK. The orphan receptors COUP-TF and HNF-4 serve as accessory factors required for induction of phosphoenolpyruvate carboxykinase gene transcription by glucocorticoids. Proc Natl Acad Sci USA. 1995;92(2):412-416.
51. Hall RK, Yamasaki T, Kucera T, Waltner-Law M, O'Brien R, Granner DK. Regulation of phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein-1 gene expression by insulin. The role of winged helix/forkhead proteins. J Biol Chem. 2000;275(39):30169-30175.
52. Wang JC, Stromstedt PE, O'Brien RM, Granner DK. Hepatic nuclear factor 3 is an accessory factor required for the stimulation of phosphoenolpyruvate carboxykinase gene transcription by glucocorticoids. Mol Endocrinol. 1996;10(7):794-800.
53. Herzog B, Hall RK, Wang XL, Waltner-Law M, Granner DK. Peroxisome proliferator-activated receptor γ coactivator-1α, as a transcription amplifier, is not essential for basal and hormoneinduced phosphoenolpyruvate carboxykinase gene expression. Mol Endocrinol. 2004;18(4):807-819.
54. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-γ coactivator 1 α (PGC-1 α): transcriptional coactivator and metabolic regulator. Endocr Rev. 2003;24(1):78-90.
55. Wang XL, Herzog B, Waltner-Law M, Hall RK, Shiota M, Granner DK. The synergistic effect of dexamethasone and all-transretinoic acid on hepatic phosphoenolpyruvate carboxykinase gene expression involves the coactivator p300. J Biol Chem. 2004; 279(33):34191-34200.
56. Yoon JC, Puigserver P, Chen G, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001;413(6852):131-138.
57. Lemberger T, Staels B, Saladin R, Desvergne B, Auwerx J, Wahli W. Regulation of the peroxisome proliferator-activated receptor α gene by glucocorticoids. J Biol Chem. 1994;269(40):24527-24530.
58. Rhee J, Inoue Y, Yoon JC, et al. Regulation of hepatic fasting response by PPARγ coactivator-1α (PGC-1): requirement for hepatocyte nuclear factor 4α in gluconeogenesis. Proc Natl Acad Sci USA. 2003;100(7):4012-4017.
59. Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1α interaction. Nature. 2003;423(6939):550-555.
60. Scott DK, O'Doherty RM, Stafford JM, Newgard CB, Granner DK. The repression of hormone-activated PEPCK gene expression by glucose is insulin-independent but requires glucose metabolism. J Biol Chem. 1998;273(37):24145-24151.
61. Wang JC, Stafford JM, Scott DK, Sutherland C, Granner DK. The molecular physiology of hepatic nuclear factor 3 in the regulation of gluconeogenesis. J Biol Chem. 2000;275(19):14717-14121.
62. Hall RK, Wang XL, George L, Koch SR, Granner DK. Insulin represses phosphoenolpyruvate carboxykinase gene transcription by causing the rapid disruption of an active transcription complex: a potential epigenetic effect. Mol Endocrinol. 2007;21(2):550-563.
63. Ichijo T, Voutetakis A, Cotrim AP, et al. The Smad6-histone deacetylase 3 complex silences the transcriptional activity of the glucocorticoid receptor: potential clinical implications. J Biol Chem. 2005;280(51):42067-42077.
64. Nader N, Ng SS, Lambrou GI, et al. AMPK regulates metabolic actions of glucocorticoids by phosphorylating the glucocorticoid receptor through p38 MAPK. Mol Endocrinol. 2010;24(9):1748-1764.
65. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1(1):15-25.
66. Cao G, Liang Y, Broderick CL, et al. Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem. 2003;278(2):1131-1136.
67. Grefhorst A, van Dijk TH, Hammer A, et al. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab. 2005;289(5):E829-E838.
68. Laffitte BA, Chao LC, Li J, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA. 2003;100(9):5419-5424.
69. Commerford SR, Vargas L, Dorfman SE, et al. Dissection of the insulin-sensitizing effect of liver X receptor ligands. Mol Endocrinol. 2007;21(12):3002-3012.
70. Nader N, Ng SS, Wang Y, Abel BS, Chrousos GP, Kino T. Liver x receptors regulate the transcriptional activity of the glucocorticoid receptor: implications for the carbohydrate metabolism. PLoS One. 2012;7(3):e26751.
71. Renga B, Mencarelli A, D'Amore C, et al. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. FASEB J. 2012;26(7):3021-3031.
72. Lu TT, Makishima M, Repa JJ, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell. 2000;6(3):507-515.
73. Lu Y, Xiong X, Wang X, et al. Yin Yang 1 promotes hepatic gluconeogenesis through upregulation of glucocorticoid receptor. Diabetes. 2013;62(4):1064-1073.
74. Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005;18(5):601-607.
75. Murphy PJ, Morishima Y, Kovacs JJ, Yao TP, Pratt WB. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J Biol Chem. 2005;280(40):33792-33799.
76. Winkler R, Benz V, Clemenz M, et al. Histone deacetylase 6 (HDAC6) is an essential modifier of glucocorticoid-induced hepatic gluconeogenesis. Diabetes. 2012;61(2):513-523.
77. Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 2005;146(3):984-991.
78. Du K, Herzig S, Kulkarni RN, Montminy M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science. 2003;300(5625):1574-1577.
79. Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesityinduced insulin resistance. Cell Metab. 2007;5(3):167-179.
80. Shibli-Rahhal A, Van Beek M, Schlechte JA. Cushing's syndrome. Clin Dermatol. 2006;24(4):260-265.
81. Taskinen MR, Nikkila EA, Pelkonen R, Sane T. Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome. J Clin Endocrinol Metab. 1983;57(3):619-626.
82. Dolinsky VW, Douglas DN, Lehner R, Vance DE. Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone. Biochem J. 2004;378(Pt 3):967-974.
83. Kirk CJ, Verrinder TR, Hems DA. Fatty acid synthesis in the perfused liver of adrenalectomized rats. Biochem J. 1976;156(3): 593-602.
84. Mangiapane EH, Brindley DN. Effects of dexamethasone and insulin on the synthesis of triacylglycerols and phosphatidylcholine and the secretion of very-low-density lipoproteins and lysophosphatidylcholine by monolayer cultures of rat hepatocytes. Biochem J. 1986;233(1):151-160.
85. Cai Y, Song Z, Wang X, Jiao H, Lin H. Dexamethasone-induced hepatic lipogenesis is insulin dependent in chickens (Gallus gallus domesticus). Stress. 2011;14(3):273-281.
86. Diamant S, Shafrir E. Modulation of the activity of insulin-dependent enzymes of lipogenesis by glucocorticoids. Eur J Biochem. 1975;53(2):541-546.
87. Lemke U, Krones-Herzig A, Berriel Diaz M, et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab. 2008;8(3):212-223.
88. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415-425.
89. Revollo JR, Oakley RH, Lu NZ, et al. HES1 is a master regulator of glucocorticoid receptor-dependent gene expression. Sci Signal. 2013;6(304):ra103.
90. Chen W, Roeder RG. The Mediator subunit MED1/TRAP220 is required for optimal glucocorticoid receptor-mediated transcription activation. Nucleic Acids Res. 2007;35(18):6161-6169.
91. Chen W, Roeder RG. Mediator-dependent nuclear receptor function. Semin Cell Dev Biol. 2011;22(7):749-758.
92. Jia Y, Viswakarma N, Fu T, Yu S, Rao MS, Borensztajn J, Reddy JK. Conditional ablation of mediator subunit MED1 (MED1/ PPARBP) gene in mouse liver attenuates glucocorticoid receptor agonist dexamethasone-induced hepatic steatosis. Gene Expr. 2009;14(5):291-306.
93. Despreś JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition. 1993;9(5):452-459.
94. Arnaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing's syndrome. Pituitary. 2004;7(4):253-256.
95. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf). 2004; 61(6):768-777.
96. Peckett AJ, Wright DC, Riddell MC., The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism. 2011;60(11): 1500-1510.
97. Harris C, Roohk DJ, Fitch M, Boudignon BM, Halloran BP, Hellerstein MK. Large increases in adipose triacylglycerol flux in Cushingoid CRH-Tg mice are explained by futile cycling. Am J Physiol Endocrinol Metab. 2013;304(3):E282-E293.
98. Yu CY, Mayba O, Lee JV, Tran J, Harris C, Speed TP, Wang JC. Genome-wide analysis of glucocorticoid receptor binding regions in adipocytes reveal gene network involved in triglyceride homeostasis. PLoS One. 2010;5(12):e15188.
99. Campbell JE, Peckett AJ, D'Souza AM, Hawke TJ, Riddell MC. Adipogenic and lipolytic effects of chronic glucocorticoid exposure. Am J Physiol Cell Physiol. 2011;300(1):C198-C209.
100. Pantoja C, Huff JT, Yamamoto KR. Glucocorticoid signaling defines a novel commitment state during adipogenesis in vitro. Mol Biol Cell. 2008;19(10):4032-4041.
101. Gray NE, Lam LN, Yang K, Zhou AY, Koliwad S, Wang JC. Angiopoietin-like 4 (Angptl4) protein is a physiological mediator of intracellular lipolysis in murine adipocytes. J Biol Chem. 2012; 287(11):8444-8456.
102. Koliwad SK, Kuo T, Shipp LE, et al. Angiopoietin-like 4 (ANGPTL4, fasting-induced adipose factor) is a direct glucocorticoid receptor target and participates in glucocorticoid-regulated triglyceride metabolism. J Biol Chem. 2009;284(38):25593-25601.
103. Zierath JR, Wallberg-Henriksson H. From receptor to effector: insulin signal transduction in skeletal muscle from type II diabetic patients. Ann NY Acad Sci. 2002;967:120-134.
104. Kuo T, Harris CA, Wang JC. Metabolic functions of glucocorticoid receptor in skeletal muscle. Mol Cell Endocrinol. 2013; 380(1-2):79-88.
105. Watson ML, Baehr LM, Reichardt HM, Tuckermann JP, Bodine SC, Furlow JD. A cell-autonomous role for the glucocorticoid receptor in skeletal muscle atrophy induced by systemic glucocorticoid exposure. Am J Physiol Endocrinol Metab. 2012;302(10): E1210-E1220.
106. Clarke BA, Drujan D, Willis MS, et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 2007;6(5):376-385.
107. Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP, Leibovitch SA. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem. 2005;280(4):2847-2856.
108. Lagirand-Cantaloube J, Offner N, Csibi A, et al. The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J. 2008;27(8):1266-1276.
109. Baehr LM, Furlow JD, Bodine SC. Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids. J Physiol. 2011;589(Pt 19):4759-4776.
110. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, Furlow JD, Bodine SC. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab. 2008; 295(4):E785-E797.
111. Zhao W, Qin W, Pan J, Wu Y, Bauman WA, Cardozo C. Dependence of dexamethasone-induced Akt/FOXO1 signaling, upregulation of MAFbx, and protein catabolism upon the glucocorticoid receptor. Biochem Biophys Res Commun. 2009;378(3):668-672.
112. Ma K, Mallidis C, Bhasin S, et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab. 2003;285(2):E363-E371.
113. Gilson H, Schakman O, Combaret L, et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology. 2007;148(1):452-460.
114. Amirouche A, Durieux A-C, Banzet S, et al. Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. Endocrinology. 2009;150(1):286-294.
115. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol. 2009;296(6):C1258-C1270.
116. Morissette MR, Cook SA, Buranasombati C, Rosenberg MA, Rosenzweig A. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol. 2009;297(5): C1124-C1132.
117. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol. 2008;197(1):1-10.
118. Shimizu N, Yoshikawa N, Ito N, et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. 2011;13(2):170-182.
119. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S157-S163.
120. Weinstein SP, Paquin T, Pritsker A, Haber RS. Glucocorticoidinduced insulin resistance: dexamethasone inhibits the activation of glucose transport in rat skeletal muscle by both insulin-and non-insulin-related stimuli. Diabetes. 1995;44(4):441-445.
121. Morgan SA, Sherlock M, Gathercole LL, et al. 11β-Hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes. 2009;58(11):2506-2515.
122. Coderre L, Srivastava AK, Chiasson JL. Effect of hypercorticism on regulation of skeletal muscle glycogen metabolism by insulin. Am J Physiol. 1992;262(4 Pt 1):E427-E433.
123. Burén J, Lai Y, Lundgren M, Eriksson JW, Jensen J. Insulin action and signalling in fat and muscle from dexamethasone-treated rats. Arch Biochem Biophys. 2008;474(1):91-101.
124. Connaughton S, Chowdhury F, Attia RR, et al. Regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression by glucocorticoids and insulin. Mol Cell Endocrinol. 2010;315(1): 159-167.
125. Wu P, Inskeep K, Bowker-Kinley M, Popov K, Harris R. Mechanism responsible for inactivation of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes. Diabetes. 1999; 48(8):1593-1599.
126. Vestergaard H, Bratholm P, Christensen NJ. Increments in insulin sensitivity during intensive treatment are closely correlated with decrements in glucocorticoid receptor mRNA in skeletal muscle from patients with Type II diabetes. Clinical Science. 2001;101(5): 533-540.
127. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001;3(11):1014-1019.
128. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol. 2004;15(6):1537-1545.
129. Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. 2006;147(9):4160-4168.
130. Leis H, Page A, Ramirez A, et al. Glucocorticoid receptor counteracts tumorigenic activity of Akt in skin through interference with the phosphatidylinositol 3-kinase signaling pathway. Mol Endocrinol. 2004;18(2):303-311.
131. Hu Z, Wang H, Lee IH, Du J, Mitch WE. Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J Clin Invest. 2009;119(10):3059-3069.
132. Lee SN, Peng B, Desjardins R, Pintar JE, Day R, Lindberg I. Strainspecific steroidal control of pituitary function. J Endocrinol. 2007; 192(3):515-525.
133. Grill, V. Rundfeldt M. Abnormalities of insulin responses after ambient and previous exposure to glucose in streptozocin-diabetic and dexamethasone-treated rats. Role of hyperglycemia and increased B-cell demands. Diabetes. 1986;35(1):44-51.
134. Rafacho A, Marroqui L, Taboga SR, et al. Glucocorticoids in vivo induce both insulin hypersecretion and enhanced glucose sensitivity of stimulus-secretion coupling in isolated rat islets. Endocrinology. 2010;151(1):85-95.
135. Nicod N, Giusti V, Besse C, Tappy L. Metabolic adaptations to dexamethasone-induced insulin resistance in healthy volunteers. Obes Res. 2003;11(5):625-631.
136. Viguerie N, Picard F, Hul G, et al. Multiple effects of a short-term dexamethasone treatment in human skeletal muscle and adipose tissue. Physiol Genomics. 2012;44(2):141-51.
137. Ranta F, Avram D, Berchtold S, et al. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes. 2006;55(5):1380-1390.
138. Reich E, Tamary A, Sionov RV, Melloul D. Involvement of thioredoxin-interacting protein (TXNIP) in glucocorticoid-mediated β cell death. Diabetologia. 2012;55(4):1048-1057.
139. Ullrich S, Berchtold S, Ranta F, et al. Serum-and glucocorticoidinducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes. 2005;54(4):1090-1099.
140. Chen J, Hui ST, Couto FM, et al. Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic β-cell mass and protects against diabetes. FASEB J. 2008;22(10):3581-3594.
141. Bernal-Mizrachi C, Weng S, Feng C, et al. Dexamethasone induction of hypertension and diabetes is PPAR-α dependent in LDL receptor-null mice. Nat Med. 2003;9(8):1069-1075.
142. Bernal-Mizrachi C, Xiaozhong L, Yin L, et al. An afferent vagal nerve pathway links hepatic PPARα activation to glucocorticoidinduced insulin resistance and hypertension. Cell Metab. 2007; 5(2):91-102.
143. Yi CX, Foppen E, Abplanalp W, et al. Glucocorticoid signaling in the arcuate nucleus modulates hepatic insulin sensitivity. Diabetes. 2012;61(2):339-345.
144. Brandish PE, Anderson K, Baltus GA, et al. The preclinical efficacy, selectivity and pharmacologic profile of MK-5932, an insulin-sparing selective glucocorticoid receptor modulator. Eur J Pharmacol. 2014;724:102-111.
145. De Bosscher K. Selective glucocorticoid receptor modulators. J Steroid Biochem Mol Biol. 2010;120(2-3):96-104.